Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Work In Process (2021 - 2025)

Mirum Pharmaceuticals has reported Work In Process over the past 5 years, most recently at $18.5 million for Q4 2025.

  • Quarterly results put Work In Process at $18.5 million for Q4 2025, up 14.82% from a year ago — trailing twelve months through Dec 2025 was $18.5 million (up 14.82% YoY), and the annual figure for FY2025 was $18.5 million, up 14.82%.
  • Work In Process for Q4 2025 was $18.5 million at Mirum Pharmaceuticals, up from $18.3 million in the prior quarter.
  • Over the last five years, Work In Process for MIRM hit a ceiling of $18.5 million in Q4 2025 and a floor of $553000.0 in Q1 2022.
  • Median Work In Process over the past 5 years was $10.5 million (2023), compared with a mean of $10.2 million.
  • Biggest five-year swings in Work In Process: soared 1072.51% in 2023 and later increased 14.82% in 2025.
  • Mirum Pharmaceuticals' Work In Process stood at $570000.0 in 2021, then surged by 838.77% to $5.4 million in 2022, then surged by 84.51% to $9.9 million in 2023, then surged by 62.96% to $16.1 million in 2024, then grew by 14.82% to $18.5 million in 2025.
  • The last three reported values for Work In Process were $18.5 million (Q4 2025), $18.3 million (Q3 2025), and $16.3 million (Q2 2025) per Business Quant data.